Please assess the completion status of the following clinical trial:

Trial Title: Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female and male patients aged 19 years or older (Korea) and aged 20 years or older (Taiwan)~* Diagnosis of NVAF~* Patients for whom the decision to initiate treatment with rivaroxaban is made as per physician's routine treatment practice~* Treatment naïve regarding stroke prevention for atrial fibrillation~* Signed informed consent~Exclusion Criteria:~* Contraindications for rivaroxaban according to the local market authorization/summary of product characteristics (SmPC)~* Patients participating in an investigational program with interventions outside of routine clinical practice

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment-naïve NVAF patients in Korea and Taiwan (Type: None): Patients will be followed according to routine medical practice and the frequency of visits and procedures will be performed under routine conditions. NVAF: Non-valvular atrial fibrillation

Based on this trial design, predict the completion outcome and termination type (if applicable).